Cellectis S.A. Sustainability Profile
Cellectis S.A., a pioneering biotechnology company headquartered in France, is at the forefront of gene-editing technology. Founded in 1999, Cellectis has established itself as a leader in the development of innovative CAR-T cell therapies, focusing on treating various cancers and genetic disorders. With a strong presence in Europe and North America, the company leverages its proprietary TALEN® technology to create unique, targeted gene-editing solutions. Cellectis' core offerings include allogeneic CAR-T therapies, which are designed to enhance the efficacy and safety of cancer treatments. The company has achieved significant milestones, including partnerships with major pharmaceutical firms and advancements in clinical trials, solidifying its position in the competitive biotech landscape. With a commitment to transforming patient care, Cellectis continues to push the boundaries of genetic engineering and cellular therapies.
DitchCarbon Score
How does Cellectis S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cellectis S.A.'s score of 26 is lower than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cellectis S.A.'s reported carbon emissions
Cellectis S.A., headquartered in France, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Cellectis may not have established formal commitments to reduce its carbon footprint or may not publicly disclose such information at this time. In the context of the biotechnology industry, many companies are increasingly adopting science-based targets and sustainability initiatives to address climate change. However, without specific emissions data or commitments from Cellectis, it is unclear how the company aligns with these industry trends.
How Carbon Intensive is Cellectis S.A.'s Industry?
How Carbon Intensive is Cellectis S.A.'s Location?
Cellectis S.A.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cellectis S.A. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
